ENGOT-EN1/FANDANGO: A randomized double-blind phase II trial of combination chemotherapy with nintedanib or placebo for patients with endometrial cancer

Update Il y a 4 ans
Reference: EUCTR2016-000193-38

Woman Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

Primary objective: To compare Progression free survival (PFS). Progression Free Survival (PFS) is de-fined as the time from randomization until disease progression or death by any cause. The progression events are defined by RECIST 1.1 criteria


Inclusion criteria

  • Histological confirmed endometrial cancer. (FIGO 2009) stage 3C2 or stage 4 or relapsed after adjuvant therapy for stage 1-3 disease